Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer.

Boston Scientific raises full-year forecast again, fueled by strong Q2

By the numbers Q2 Net sales: $3.6 billion 11% increase year-over-year Q2 Net income: $261 million 6% increase year-over-year Q2 Earnings per share: $0.18 6%

July 27, 2023

BGB-10188 by BeiGene for Peritoneal Cancer: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 28, 2023

Ironwood’s stock drops 40% as short bowel syndrome drug shows mixed efficacy in PhIII

Ironwood Pharmaceuticals’ GLP-2 analog hit the primary endpoint in a registrational short bowel syndrome study, but fell short of key secondary outcomes in a slightly

March 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.